N -[6-(4-Butanoyl-5-methyl-1 H -pyrazol-1-yl)pyridazin-3-yl]-5-chloro-1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1 H -indole-3-carboxamide (SAR216471), a Novel Intravenous and Oral, Reversible, and Directly Acting P2Y12 Antagonist

Journal of Medicinal Chemistry

Volumn 57, Issue 17, 2014, Pages 7293-7316

  Boldron, Christophe ^a   Besse, Angélina ^a   Bordes, Marie Françoise ^a   Tissandié, Stéphanie ^a   Yvon, Xavier ^a   Gau, Benjamin ^a   Badorc, Alain ^a   Rousseaux, Tristan ^a   Barré, Guillaume ^a   Meneyrol, Jérôme ^a   Zech, Gernot ^b   Nazare, Marc ^c   Fossey, Valérie ^a   Pflieger, Anne Marie ^a   Bonnet Lignon, Sandrine ^a   Millet, Laurence ^a   Briot, Christophe ^a   Dol, Frédérique ^a   Hérault, Jean Pascal ^a   Savi, Pierre ^a   Lassalle, Gilbert ^a   Delesque, Nathalie ^a   Herbert, Jean Marc ^a   Bono, Françoise ^a   more..

^a SANOFI   (France)

^b Sanofi R and D   (Germany)

^c LEIBNIZ INSTITUT FÜR MOLEKULARE PHARMAKOLOGIE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS AFFECTING PROTEIN METABOLISM; ANTITHROMBOCYTIC AGENT; N [6 (4 BUTANOYL 5 METHYL 1H PYRAZOL 1 YL)PYRIDAZIN 3 YL] 5 CHLORO 1 [2 (4 METHYLPIPERAZIN 1 YL) 2 OXOETHYL] 1H INDOLE 3 CARBOXAMIDE; PURINERGIC P2Y12 RECEPTOR; UNCLASSIFIED DRUG; ADENOSINE DIPHOSPHATE; INDOLE DERIVATIVE; N-(6-(4-BUTANOYL-5-METHYL-1H-PYRAZOL-1-YL)PYRIDAZIN-3-YL)-5-CHLORO-1-(2-(4-METHYLPIPERAZIN-1-YL)-2-OXOETHYL)-1H-INDOLE-3-CARBOXAMIDE; PURINERGIC P2 RECEPTOR ANTAGONIST; PYRIDAZINE DERIVATIVE;

ANIMAL CELL; ANTICOAGULATION; ARTICLE; HUMAN; HUMAN CELL; MALE; NONHUMAN; RAT; THROMBOCYTE AGGREGATION; ACUTE CORONARY SYNDROME; ANIMAL; BINDING COMPETITION; CHEMICAL MODEL; CHEMICAL STRUCTURE; CHO CELL LINE; CRICETULUS; DRUG EFFECTS; GENETICS; HAMSTER; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; ORAL DRUG ADMINISTRATION; SPRAGUE DAWLEY RAT; SYNTHESIS; THROMBOSIS;

ACUTE CORONARY SYNDROME; ADENOSINE DIPHOSPHATE; ADMINISTRATION, ORAL; ANIMALS; BINDING, COMPETITIVE; CHO CELLS; CRICETINAE; CRICETULUS; HUMANS; INDOLES; INJECTIONS, INTRAVENOUS; MALE; MODELS, CHEMICAL; MOLECULAR STRUCTURE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2 RECEPTOR ANTAGONISTS; PYRIDAZINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, PURINERGIC P2Y12; THROMBOSIS;

EID: 84907192988     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm500588w     Document Type: Article

References (47)

1. Kunapuli, S. P. P2 receptors and platelet activation TheScientificWorldJournal 2002, 2, 424-433
2. Kauffenstein, G.; Bergmeier, W.; Eckly, A.; Ohlmann, P.; Leon, C.; Cazenave, J. P.; Nieswandt, B.; Gachet, C. The P2Y12 receptor induces platelet aggregation through weak activation of the αIIbβ3 integrin-a phosphoinositide 3-kinase-dependent mechanism FEBS Lett. 2001, 505 (2) 281-290
3. Maffrand, J. P. The story of clopidogrel and its predecessor, ticlopidine: Could these major antiplatelet and antithrombotic drugs be discovered and developed today? C. R. Chim. 2012, 15, 737-743
4. Angiolillo, D. J. The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day Drugs 2012, 72 (16) 2087-2116
5. Feliste, R.; Delebassee, D.; Simon, M. F.; Chap, H.; Defreyn, G.; Vallee, E.; Douste-Blazy, L.; Maffrand, J. P. Effect of PCR 4099 on ADP-induced calcium movements and phosphatidic acid production in rat platelets Thromb. Res. 1987, 48 (4) 403-415
6. Hollopeter, G.; Jantzen, H. M.; Vincent, D.; Li, G.; England, L.; Ramakrishnan, V.; Yang, R. B.; Nurden, P.; Nurden, A.; Julius, D.; Conley, P. B. Identification of the platelet ADP receptor targeted by antithrombotic drugs Nature 2001, 409, 202-207
7. Robert, A. N. Identification of the P2Y12 receptor: a novel member of the P2Y family of receptors activated by extracellular nucleotides Mol. Pharmacol. 2001, 60 (3) 416-420
8. Savi, P.; Herbert, J. M. clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis Semin. Thromb. Hemostasis 2005, 31, 174-83
9. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) Lancet 1996, 348, 1329-1339
10. The Clopidogrel in Unstable Angina To Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N. Engl. J. Med. 2001, 345, 494-502
11. Niitsu, Y.; Jakubowski, J. A.; Sugidachi, A.; Asai, F. Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity Semin. Thromb. Hemostasis 2005, 31, 184-194
12. Savi, P.; Herbert, J. M.; Pflieger, A. M.; Dol, F.; Delebassee, D.; Combalbert, J.; Defreyn, G.; Maffrand, J. P. Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel Biochem. Pharmacol. 1992, 44 (3) 527-532
13. Schroer, K. The basic pharmacology of ticlopidine and clopidogrel Platelets 1993, 4 (5) 252-261
14. van Giezen, J. J. J.; Humphries, R. G. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists Semin. Thromb. Hemostasis 2005, 31, 195-204
15. Springthorpe, B.; Bailey, A.; Barton, P.; Birkinshaw, T. N.; Bonnert, R. V.; Brown, R. C.; Chapman, D.; Dixon, J.; Guile, S. D.; Humphries, R. G.; Hunt, S. F.; Ince, F.; Ingall, A. H.; Kirk, I. P.; Leeson, P. D.; Leff, P.; Lewis, R. J.; Martin, B. P.; McGinnity, D. F.; Mortimore, M. P.; Paine, S. W.; Pairaudeau, G.; Patel, A.; Rigby, A. J.; Riley, R. J.; Teobald, B. J.; Tomlinson, W.; Webborn, P. J. H.; Willis, P. A. From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis Bioorg. Med. Chem. Lett. 2007, 17, 6013-6018
16. Huber, K.; Hamad, B.; Kirkpatrick, P. Fresh from the pipeline. Ticagrelor Nat. Rev. Drug Discovery 2011, 10, 255-256
17. Gurbel, P. A.; Kereiakes, D. J.; Tantry, U. S. Ticagrelor for the treatment of arterial thrombosis Expert Opin. Pharmacother. 2010, 11, 2251-2259
18. Gurbel, P. A.; Kereiakes, D.; Tantry, U. S. Elinogrel Potassium Drugs Future 2010, 35, 885-892
19. Ueno, M.; Rao, S. V.; Angiolillo, D. J. Elinogrel: pharmacological principles, preclinical and early phase clinical testing Future Cardiol. 2010, 6, 445-453
20. Oestreich, J. H. Elinogrel, a reversible P2Y12 receptor antagonist for the treatment of acute coronary syndrome and prevention of secondary thrombotic events Curr. Opin. Invest. Drugs 2010, 11, 340-348
21. Berger, J. S.; Roe, M. T.; Gibson, C. M.; Kilaru, R.; Green, C. L.; Melton, L.; Blankenship, J. D.; Metzger, D. C.; Granger, C. B.; Gretler, D. D.; Grines, C. L.; Huber, K.; Zeymer, U.; Buszman, P.; Harrington, R. A.; Armstrong, P. W. Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the early rapid reversal of platelet thrombosis with intravenous elinogrel before PCI to optimize reperfusion in acute myocardial infarction (ERASE MI) Am. Heart J. 2009, 158, 998-1004
22. Etter, M. C.; Urbakzyk-Lipkowska, Z.; Zia-Ebrahimi, S. M.; Panunto, T. W. Hydrogen bond directed cocrystallization and molecular recognition properties of diarylureas J. Am. Chem. Soc. 1990, 112, 8415-8426
23. Dennis, M. S.; Zhang, M.; Meng, Y. G.; Kadkhodayan, M.; Kirchhofer, D.; Combs, D.; Damico, L. A. Albumin binding as a general strategy for improving the pharmacokinetics of proteins J. Biol. Chem. 2002, 38, 35035-35043
24. Ames, B. N.; Mccann, J.; Yamasaki, E. Methods for detecting carcinogens and mutagens with the Salmonella /mammalian-microsome mutagenecity test Mutat. Res. 1975, 31, 347-364
25. Mortelmans, K.; Zeiger, E. The Ames Salmonella /microsome mutagenicity assay Mutat. Res. 2000, 455, 29-60
26. Helmick, J. S.; Martin, K. A.; Heinrich, J. L.; Novak, M. Mechanism of the reaction at carbon and nitrogen nucleophiles with the model carcinogens O -pivaloyl- N -arylhydroxylamines: competing SN2 substitution and SN1 solvolysis J. Am. Chem. Soc. 1991, 113, 3459-3466
27. Borosky, G. L. Ultimate carcinogenic metabolites from aromatic and heterocyclic aromatic amines: a computational study in relation to their mutagenic potency Chem. Res. Toxicol. 2007, 20, 171-180
28. Dipple, A. DNA adducts of chemical carcinogens Carcinogenesis 1995, 16, 437-441
29. Benigni, R. Structure-activity relationship studies of chemical mutagens and carcinogens: mechanistic investigations and prediction approaches Chem. Rev. 2005, 105, 1767-1800
30. Benigni, R.; Giuliani, A.; Franke, R.; Gruska, A. Quantitative structure-activity relationship of mutagenic and carcinogenic aromatic amines Chem. Rev. 2000, 100, 3697-3714
31. Kadlubar, F. F.; Beland, F. A. Chemical Properties of Ultimate Carcinogenic Metabolites of Arylamines and Arylamides. Polycyclic Hydrocarbons and Carcinogenesis; American Chemical Society: Washington, DC, 1985; pp 341-370.
32. Chung, K. T.; Kirkovsky, L.; Kirkovsky, A.; Purcell, W. P. Review of Mutagenicity of Monocyclic Aromatic amines: quantitative structure-activity relationships Mutat. Res. 1997, 387, 1-16
33. Colvin, M. E.; Hatch, F. T.; Felton, J. S. Chemical and biological factors affecting mutagen potency Mutat. Res. 1998, 400, 479-492
34. Benigni, R.; Bossa, C.; Netzeva, T.; Rodomonte, A.; Tsakovska, I. Mechanistic QSAR of aromatic amines: new models for discriminating between homocyclic mutagens and nonmutagens, and validation of models for carcinogens Environ. Mol. Mutagen. 2007, 48, 754-771
35. Benigni, R.; Passerini, L. Mutat. Res. 2002, 511, 191-206
36. Kimball, R. F. The mutagenicity of hydrazine and some of its derivatives Mutat. Res. 1977, 39 (2) 111-126
37. 12receptor inhibitors? Thromb. Res. [Online early access]. DOI: 10.1016/j.thromres.2014.06.034. Published Online: July 11, 2014.
38. Mackie, R. K.; Mhatre, S.; Tedder, J. M. Carbon-trifluoroacylation-a convenient route to carboxylic acids J. Fluorine Chem. 1977, 10 (6) 437-445
39. Sakamoto, T.; Nagano, T.; Kondo, Y.; Yamanaka, H. Condensed heteroaromatic ring systems. XVII. Palladium-catalyzed cyclization of β-(2-halophenyl)amino substituted α,β-unsaturated ketones and esters to 2,3-disubstituted indoles Synthesis 1990, 3, 215-218
40. Hwu, J. R.; Patel, H. V.; Lin, R. J.; Gray, M. O. Novel methods for the synthesis of functionalized indoles from arylhydroxylamines and activated acetylenes J. Org. Chem. 1994, 59, 1577-1582
41. Duflosa, M.; Nourrissona, M. R.; Breleta, J.; Couranta, J.; LeBauta, G.; Grimaudb, N.; PetitbDuflos, J. Y. N -Pyridinylindole-3-(alkyl)carboxamides and derivatives as potential systemic and topical inflammation inhibitors Eur. J. Med. Chem. 2001, 36 (6) 545-553
42. Brooks, D. W.; Lu, L. D. L.; Masuniune, S. C-Acylation under virtually neutral conditions Angew. Chem., Int. Ed. Engl. 1979, 18, 72-74
43. Hu, F. Z.; Zhang, G. F.; Liu, B.; Zou, X. M.; Zhu, Y. Q.; Yang, H. Z. A new method for the synthesis and herbicidal activity of 3-phenoxy-6-(1 H -(substituted)pyrazol-1-yl) pyridazines J. Heterocycl. Chem. 2009, 46, 584-590
44. Arvela, K.; Leadbeater, N. E. Fast and easy halide exchange in aryl halides Synlett 2003, 8, 1145-1148
45. Savi, P.; Herbert, J. M. Use of radiolabeled 2-methylthio-ADP to study P2Y receptors on platelets and cell lines Methods Mol. Biol. 2004, 273, 115-124
46. Ratkowsky, D. A.; Reedy, T. J. Choosing near-linear parameters in the four-parameter log model for radioligand and related assays Biometrics 1986, 42, 575-582
47. Born, G. V. Aggregation of blood platelets by adenosine diphosphate and its reversal Nature 1962, 194, 927-929